Quote:
Originally Posted by msladyinca
Been there, done that, and please don't roll your eyes at me or the published data (that borders on rudeness)..and I don't need to re-inform squat, you are more than welcome to believe whatever TRIAL guru opinions you want to, but if you start posting falsehoods, as in your ealier post, I won't hesitate to point them out for ALL to see.
Good evening to you.
Lauren
|
Well, it seems that despite the marketing/sales efforts of Biogen/Elan and the hype that is being created by some with this drug, the financial world (and that is what big pharma is all about) is being far more cautious as is demonstrated by this press release yesterday:
Quote:
BOSTON, Oct 23 (Reuters) Over the past month or so, analysts have drawn down their 2006 sales forecasts as it becomes clear that doctors wary of the risk of the rare but potentially fatal brain disease PML are reserving the drug as a treatment of last resort.
The drug, which is made by Biogen Idec Inc. and Irish partner Elan Corp., had been expected by some analysts to generate sales this year of more than $100 million, but those figures have dropped dramatically.
Ian Hunter, an analyst at Goodbody stockbrokers in Dublin, said on Monday that he has cut his full-year Tysabri forecast to $25.7 million from $78 million, in part because of continuing safety concerns.
A survey of 63 neurologists conducted by Reuters Primary Research indicates that in 2006 Tysabri will be used in less than 1 percent of multiple sclerosis patients -- translating into revenue of under $30 million.
And more than 75 percent of the patients who had used Tysabri prior to its 2005 suspension have decided not to use it since its reintroduction, the survey showed
|
Like I've said many times, it will take about a year of general MS population use before we start to see any meaningful results from Tysabri.
Harry